Alexander D. Drilon

Retreatment with First-Generation Selective RET Inhibitors in RET -Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry

A. Marinello, Julia K. Rotow, Meghanne Lomibao, Daniela Miliziano et autres

PURPOSE: In RET-rearranged non-small cell lung cancer (NSCLC), treatment options after first-generation selective RET inhibitors (SRI) are limited, and the value of SRI retreatment remains unclear. This study evaluates outcomes of SRI retreatment. EXPERIMENTAL DESIGN: This multicenter retrospective study included patients with …

fr, us, it, ca, be, es (code pays fourni par la source)

Abstract 2498: OncoKB™, MSK’s precision oncology knowledge base: 2025 updates

Sarah P. Suehnholz, Ritika Kundra, Moriah Heller Nissan, Calvin Lu et autres

Abstract OncoKB™, a precision oncology knowledgebase developed at Memorial Sloan Kettering Cancer Center (MSK), provides expert-reviewed interpretations of the biological function and clinical actionability for >8,000 somatic alterations in 950 cancer-associated genes. It remains the only somatic cancer variant knowledgebase partially recognized …

us (code pays fourni par la source)

Abstract 2434: Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET -rearranged advanced NSCLC

Daniela Miliziano, Julia K. Rotow, Meghanne Lomibao, Tolulope Adeyelu et autres

Abstract Background: RET fusions occur in ∼1-2% of advanced NSCLC (aNSCLC). Selective RET inhibitors (SRIs) significantly improve outcomes, yet ∼10% of patients progress by 6 months and ∼30% by 12 months. Predictors of response or early progression remain poorly defined. Methods: A …

fr, us, es, ca, it, be, de, gb, br, ar, pl, il (code pays fourni par la source)

Abstract 7042: Missense mutant p53 regulates DNA replication and damage response to promote resistance to targeted therapies in ALK fusion lung adenocarcinoma.

Esther Redín, Bárbara Piffero Mello, Yingian A. Zhan, Nicholas Socci et autres

Abstract ALK gene fusions drive oncogenesis in ∼5% of lung adenocarcinomas (LUADs), and ALK tyrosine kinase inhibitors (TKIs) such as lorlatinib have improved outcomes. However, acquired resistance remains a challenge, with >30% of mechanisms unknown. To uncover novel drivers of resistance, we …

us (code pays fourni par la source)

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

Chaitanya Bandlamudi, Daniel M. Muldoon, Ino de Bruijn, Mingxuan Zhang et autres

The oncogenic impact of somatic driver alterations is shaped by tissue context. Classifying alterations by cancer type and evaluating their context-specific properties requires large cohorts of genomically profiled and clinically annotated tumors. Here, we define cancer type-specific patterns of driver alterations, including …

us (code pays fourni par la source)

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study

Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones, Silvia Stacchiotti et autres

Advanced tumors harboring SWI/SNF mutations are rare and aggressive. Often presenting in young patients, treatment options are limited. This phase II basket study (NCT02601950) assessed oral tazemetostat, an EZH2 inhibitor, at 800 mg twice daily (N = 129). Cohorts included malignant rhabdoid …

us, be, gb, it, ca, tw, fr (code pays fourni par la source)

Table S2 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa J. Cooper, Stephen V. Liu, Oliver Gautschi et autres

Acquired genomic alterations identified by post-progression biopsies after selective RET inhibitors

Table S1 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa J. Cooper, Stephen V. Liu, Oliver Gautschi et autres

Clinical and Molecular Characteristics of Cases of RET Gain Identified by Next-Generation Sequencing after Selective RET Inhibitors

Supplementary Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa J. Cooper, Stephen V. Liu, Oliver Gautschi et autres

Pre- and post-SRI next-generation sequencing results provided

Table S3 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa J. Cooper, Stephen V. Liu, Oliver Gautschi et autres

Clinical and Molecular Characteristics of Cases of Acquired MET Amplification Identified by Next-Generation Sequencing after Selective RET Inhibitors

Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa J. Cooper, Stephen V. Liu, Oliver Gautschi et autres

AbstractPurpose: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. Experimental Design: We established “RETgistry,” …

Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK -Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers

Emily A. Miao, Beow Y. Yeap, Sameh Daher, Meghanne Lomibao et autres

PURPOSE Anaplastic lymphoma kinase (ALK) is an established therapeutic target in non–small cell lung cancer (NSCLC), predominantly identified in adenocarcinomas. However, ALK rearrangements also occur in de novo squamous and adenosquamous NSCLCs and their clinicogenomic features remain poorly defined. METHODS This multi-institutional …

us (code pays fourni par la source)